吲哚布芬联合替格瑞洛治疗急性ST段抬高型心肌梗死PCI术后患者的效果

Effect of indobufen combined with ticagrelor on patients with acute ST-segment elevation myocardial infarction after PCI

目的观察吲哚布芬联合替格瑞洛治疗急性ST段抬高型心肌梗死(ST segment elevation myocardial infarction,STEMI)经皮冠状动脉介入术(percutaneous coronary intervention,PCI)术后患者的效果。方法选取212例行PCI治疗的STEMI患者作为研究对象,运用随机数字表法分为对照组(n=106)和观察组(n=106)。对照组给予替格瑞洛加阿司匹林治疗,观察组给予吲哚布芬联合替格瑞洛治疗。比较两组治疗前后心功能指标水平、心肌血流再灌注情况和不良心血管事件(major adverse cardiac events,MACE)发生情况。结果观察组治疗后血浆N末端脑钠肽前体(N-terminal pro-brain natriuretic peptide,NT-proBNP)、左室舒张末期内径(left ventricular end-diastolic diameter,LVEDD)、左室收缩末期内径(left ventricular end-systolic diameter,LVESD)明显低于对照组,左室射血分数(left ventricular ejection fraction,LVEF)明显高于对照组,差异均有统计学意义(P<0.05);观察组心肌梗死溶栓(thrombolysis in myocardial infarction,TIMI)血流分级和TIMI心肌灌注分级(TIMI myocardial perfusion grade,TMPG)及无复流率均明显高于对照组,差异均有统计学意义(P<0.05);观察组MACE发生率为3.77%,明显低于对照组的12.26%,差异有统计学意义(P<0.05)。结论吲哚布芬联合替格瑞洛治疗可显著改善STEMI经PCI术后患者的心功能,改善心肌血流再灌注,降低MACE发生率的效果优于替格瑞洛加阿司匹林的效果。

Objective To study effects of indobufen combined with ticagrelor on patients with acute ST-segment elevation myocardial infarction(STEMI)after percutaneous coronary intervention(PCI).Methods 212 STEMI patients undergoing PCI treatment were selected as the research subjects,and were divided into a control group(n=106)and an observation group(n=106)by using random number table method.The control group was treated with tigriluo plus ASpirin,while the observation group was treated with indobufen combined with tigriluo.Then,the levels of cardiac function indexes,myocardial blood flow reperfusion and major adverse cardiac events(MACE)before and after treatment were compared between the two groups.Results The levels of plasma N-terminal pro-brain natriuretic peptide(NT-proBNP),left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)of the observation group after treatment were significantly lower than those of the control group;the left ventricular ejection fraction(LVEF)was significantly higher than that of the control group;and the differences were statistically significant(P<0.05).The thrombolysis in myocardial infarction(TIMI)blood flow grade,the TIMI myocardial perfusion grade(TMPG)and no-reflow rate in the observation group were significantly higher than those in the control group,and the differences were statistically significant(P<0.05).Further,the incidence of MACE in the observation group was 3.77%,which was significantly lower than 12.26%in the control group,and the difference was statistically significant(P<0.05).Conclusions For the STEMI patients undergoing PCI,indobufen combined with ticagrelor can significantly improve the cardiac function,improve the myocardial blood flow reperfusion,and reduce the incidence of adverse cardiovascular events.Moreover,it is superior to combined with ASpirin ticagrelor.